Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday

Key Points

• Entrada Therapeutics is set to announce its Q2 2025 earnings results on August 12th, with analysts expecting a loss of ($0.86) per share and revenue of $8.17 million.
• In the last quarterly report on May 8th, the company reported an EPS of ($0.42), exceeding estimates, though revenue fell short of expectations.
• Insider sales occurred recently, with Director Kush Parmar selling 75,000 shares at an average price of $6.91, indicating potential shifts in confidence among stakeholders.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Entrada Therapeutics to post earnings of ($0.86) per share and revenue of $8.17 million for the quarter.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.18). The company had revenue of $1.98 million during the quarter, compared to the consensus estimate of $8.17 million. Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Entrada Therapeutics Stock Down 2.1%

Entrada Therapeutics stock traded down $0.11 during mid-day trading on Friday, reaching $5.19. 308,342 shares of the company's stock were exchanged, compared to its average volume of 212,911. The business's fifty day simple moving average is $6.90 and its 200 day simple moving average is $8.99. The firm has a market capitalization of $196.96 million, a PE ratio of -2.92 and a beta of -0.12. Entrada Therapeutics has a one year low of $4.98 and a one year high of $21.79.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wall Street Zen downgraded Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $25.67.

Insider Activity

In other news, Director Kush Parmar sold 27,000 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $202,500.00. Following the completion of the sale, the director owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. The trade was a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $52,012.50. Following the completion of the sale, the insider directly owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. This trade represents a 0.63% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 254,000 shares of company stock valued at $1,782,000. Corporate insiders own 8.11% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Entrada Therapeutics stock. Geode Capital Management LLC grew its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 7.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 631,554 shares of the company's stock after acquiring an additional 42,479 shares during the period. Geode Capital Management LLC owned about 1.66% of Entrada Therapeutics worth $4,245,000 at the end of the most recent quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.